Porphyrinogens are cyclic tetrapyrroles- that is, they are a class of biochemical compounds that are composed of four pyrrole groups connected in a ring-like structure. Uroporphyrinogens are porphyrinogens that also contain a propionic acid ("P" group) and acetic acid ("A" group) side group connected to each pyrrole in the macrocyclic core (8 side groups in total, 4 Ps and 4 As). There are four variants of uroporphyrinogen (uroporphyrinogen I-IV), which are differentiated from each other by the arrangement of the P and A side groups. Uroporphyrinogen I and III are naturally occurring compounds, while uroporphyrinogen II and IV do not occur in nature and are only obtainable synthetically. Uroporphyrinogen III is of particular importance in the field of medicine due to its presence in the human body as an intermediate of the biosynthetic pathway that produces heme.
In the human body, heme biosynthesis is mostly present in the bone marrow and liver tissue.
Therefore an interruption in any of the steps in the production of heme could result in the buildup of specific toxic heme precursors leading to a group of diseases called the porphyrias, which may present differently depending on the metabolite that accumulates and site of accumulation (hepatic vs. erythropoietic).
There are eight enzymes involved in the biosynthesis of heme, and in cells, the first and last three steps of the pathway occur in the mitochondria while the rest occur in the cytosol. The production and metabolization of uroporphyrinogen III take place in the cytosol.
Uroporphyrinogen III is one of the intermediates in the 8 step biosynthesis of heme. It forms from the linear compound hydroxymethylbilane, also called preuroporphyrinogen, by the cytosolic enzyme uroporphyrinogen III synthase (UROS). The newly cyclized compound is then converted to coproporphyrinogen III by the enzyme uroporphyrinogen decarboxylase (UROD). However, in the presence of decreased UROS activity, hydroxymethylbilane may spontaneously close and form uroporphyrinogen I. Uroporphyrinogen I may then be acted upon by UROD to produce coproporphyrinogen I, which cannot undergo further metabolism, which results in the accumulation of the coproporphyrinogen I (a cytotoxic chemical), which can lead to clinically significant disease. Similarly, a deficiency or reduced activity of UROD can result in the accumulation of uroporphyrinogen III, which can then become oxidized to uroporphyrin and heptacarboxyl porphyrin. These are also toxic chemicals that can lead to sickness.
Uroporphyrinogens are cyclic tetrapyrroles (four pyrroles connected in a ring structure by methylene or methine bridges) with four propionic acid (P) groups and four acetic acid (A) groups. The various uroporphyrinogens differ by their arrangement of the side groups. The order of the side groups in uroporphyrinogen III is (in clockwise order) AP-AP-AP-PA, while the order in uroporphyrinogen I is AP-AP-AP-AP.
The group of diseases referred to as the porphyrias are metabolic disorders- they are caused by an abnormality in the function of the enzymes involved in the biosynthesis of heme. The anomaly usually manifests as an alteration in the activity (increased or decreased) of the enzyme, and most of the porphyrias have a genetic mutation that is responsible for the dysfunction. Porphyria cutanea tarda (PCT) is the lone exception, as it can develop in the absence of a gene mutation and is, in fact, most often caused by an acquired inhibitor (around 2/3 of cases). Also, most genetic mutations occur in the gene that encodes the respective synthetic heme enzyme, with exceptions including rare instances of congenital erythropoietic porphyria (CEP), in which the causative mutation is in a transcription factor that controls the expression of the enzyme uroporphyrinogen III synthase. Thus, any of the porphyrias may exhibit a predictable Mendelian genetic inheritance pattern as the genes for all the synthetic heme enzymes (or genes related to their expression) are found within the cellular genome (none of the genes are mitochondrial).
The clinical presentation of the different porphyrias depends on the noxious metabolites that accumulate, their sites of accumulation, and the method by which those metabolites get excreted. Depending on the solubility of the compounds in different cellular components, they may accumulate in different areas of the body and be excreted by the liver (in bile and feces) or by the kidneys (in urine). This excretion is useful as levels of specific porphyrins can be measured in urine and feces to aid in the diagnosis. Also, certain symptoms such as cutaneous blistering or neurovisceral manifestations (abdominal pain, vomiting, weakness, psychiatric changes) are typically seen in certain porphyrias depending on the accumulation of porphyrins in specific areas such as the skin or nervous system. Knowledge of this can be used to help aid in forming the differential diagnosis of a patient with suspected porphyria.
The impaired metabolization of uroporphyrinogen III is the cause of two known porphyrias: congenital erythropoietic porphyria (CEP) and porphyria cutanea tarda (PCT).
Congenital Erythropoietic Porphyria: Also known as Gunther disease, this porphyria is a rare autosomal recessive disorder caused by an inherited deficiency of the enzyme uroporphyrinogen III synthase (UROS). In the presence of insufficient UROS activity, hydroxymethylbilane spontaneously closes and forms the non-physiological compound uroporphyrinogen I, which is then acted upon by uroporphyrinogen decarboxylase to form coproporphyrinogen I. Coproporphyrinogen I then oxidizes spontaneously to form the porphyrins coproporphyrin I and uroporphyrin I. In CEP, these toxic porphyrins mostly accumulate in RBC precursors in the bone marrow, as well as the teeth, bones, urine, and feces. They are not significantly elevated in the liver. This leads to disease characterized by severe cutaneous photosensitivity and hemolysis.
The extent of enzyme deficiency caused by the UROS mutation in each case is the major determinant of the age of onset and severity of symptoms seen in the disease. Treatment involves avoidance of exposure to sunlight, prompt treatment of skin infections, possible RBC transfusions with iron chelation, and in severe cases allogeneic hematopoietic cell transplantation.
Porphyria Cutanea Tarda: PCT is the most common type of porphyria. It is due to a deficiency or decreased activity in the enzyme uroporphyrinogen decarboxylase (UROD) within the liver, and UROD activity less than 20% is usually required for the clinical manifestations of PCT to appear. A genetic mutation in the UROD gene can predispose one to the disease, as it will cause a decrease in UROD activity to 50%, but other various acquired factors are also needed. Therefore, penetrance is usually low in familial PCT, and there may not be an apparent family history of the disease. Most cases of PCT (~80%) in fact occur in the absence of a UROD mutation and are due exclusively to acquired factors causing a deficiency in UROD activity- these cases are referred to as "sporadic." The decreased activity of UROD in the liver leads to the accumulation of uroporphyrinogen III, which is oxidized to uroporphyrin and heptacarboxyl porphyrin. These toxic porphyrins are transported from the liver to the skin and are excreted in urine and feces. This leads to the cutaneous symptoms characteristic of PCT.
Decreased activity of UROD in the liver that is acquired environmentally or behaviorally is usually due to resultant iron accumulation or oxidative damage in hepatocytes. Thus, risk factors for iron accumulation in the liver such as inherited HFE mutations, or factors for liver damage such as alcohol abuse, smoking, and HCV infection are all implicated in the pathogenesis of PCT. Determining the presence or absence of these factors in a patient with suspected PCT is crucial as it can affect the management of the disease.
PCT generally presents in an adult with chronic blistering, hyper or hypopigmentation, and scarring in sun-exposed areas of the body. The blistering after sun exposure is usually delayed, and therefore, many patients may not be aware that sunlight is causing their skin manifestations. Hepatic transaminase elevations and hepatomegaly are also characteristic in patients with PCT, reflecting the liver damage present in the disease. Treatment involves low-dose hydroxychloroquine and phlebotomy to decrease the iron deposition in the liver, and the elimination of susceptibility factors is also essential in the treatment of PCT.
|||Phillips JD, Heme biosynthesis and the porphyrias. Molecular genetics and metabolism. 2019 Apr 22; [PubMed PMID: 31326287]|
|||Cox TC,Bawden MJ,Martin A,May BK, Human erythroid 5-aminolevulinate synthase: promoter analysis and identification of an iron-responsive element in the mRNA. The EMBO journal. 1991 Jul; [PubMed PMID: 2050125]|
|||Sutherland GR,Baker E,Callen DF,Hyland VJ,May BK,Bawden MJ,Healy HM,Borthwick IA, 5-Aminolevulinate synthase is at 3p21 and thus not the primary defect in X-linked sideroblastic anemia. American journal of human genetics. 1988 Sep; [PubMed PMID: 3414687]|
|||Battersby AR,Fookes CJ,Matcham GW,McDonald E, Biosynthesis of the pigments of life: formation of the macrocycle. Nature. 1980 May 1; [PubMed PMID: 6769048]|
|||Phillips JD,Warby CA,Whitby FG,Kushner JP,Hill CP, Substrate shuttling between active sites of uroporphyrinogen decarboxylase is not required to generate coproporphyrinogen. Journal of molecular biology. 2009 Jun 5; [PubMed PMID: 19362562]|
|||Magnus IA, Cutaneous porphyria. Clinics in haematology. 1980 Jun; [PubMed PMID: 7398149]|
|||Szilágyi A,Györffy D,Závodszky P, Segment swapping aided the evolution of enzyme function: The case of uroporphyrinogen III synthase. Proteins. 2017 Jan; [PubMed PMID: 27756106]|
|||Phillips JD,Bergonia HA,Reilly CA,Franklin MR,Kushner JP, A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proceedings of the National Academy of Sciences of the United States of America. 2007 Mar 20; [PubMed PMID: 17360334]|
|||Phillips JD,Steensma DP,Pulsipher MA,Spangrude GJ,Kushner JP, Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007 Mar 15; [PubMed PMID: 17148589]|
|||Bissell DM,Anderson KE,Bonkovsky HL, Porphyria. The New England journal of medicine. 2017 Aug 31; [PubMed PMID: 28854095]|
|||Desnick RJ,Astrin KH, Congenital erythropoietic porphyria: advances in pathogenesis and treatment. British journal of haematology. 2002 Jun; [PubMed PMID: 12060112]|
|||Warner CA,Poh-Fitzpatrick MB,Zaider EF,Tsai SF,Desnick RJ, Congenital erythropoietic porphyria. A mild variant with low uroporphyrin I levels due to a missense mutation (A66V) encoding residual uroporphyrinogen III synthase activity. Archives of dermatology. 1992 Sep; [PubMed PMID: 1519940]|
|||Jalil S,Grady JJ,Lee C,Anderson KE, Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2010 Mar; [PubMed PMID: 19948245]|
|||Aarsand AK,Boman H,Sandberg S, Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clinical chemistry. 2009 Apr; [PubMed PMID: 19233912]|